CAS No. |
472-26-4 |
英文名称 |
5-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one |
别名 |
3β,5,14-Trihydroxy-5β,14β-bufa-20,22-dienolide;3β,5,14-Trihydroxy-5β-bufa-20,22-dienolide;Telocinobufagin;Telocinobufogenin;(3beta,5beta)-3,5,14-Trihydroxybufa-20,22-dienolide;Telobufotoxin;(3β,5β)-3,5,14-Trihydroxybufa-20,22-dienolide;NSC 119989 |
标准英文名 |
5-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one |
分子式 |
C24H34O5 |
分子量 |
402.53
|
精确分子量 |
402.24
|
SMILES |
C[C@]12CC[C@H](O)C[C@@]1(O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=COC(=O)C=C3)CC[C@]12O |
标准SMILES |
C[C@]12CC[C@H](O)C[C@@]1(O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](CC[C@@]21O)C1C=CC(=O)OC=1 |
用途 |
Telocinobufagin is used for content determination, identification, and pharmacological experiments; it exhibits significant anticancer, cardiotonic, analgesic, antiviral, anesthetic, and bone marrow-stimulating activities; it is clinically applied in the treatment of cancers such as hepatocellular carcinoma, gastric cancer, and esophageal cancer with an efficacy rate of 50–70%; it helps prevent leukopenia induced by radiotherapy and chemotherapy, enhances the therapeutic effects and tolerance to these treatments, and has been formulated into an aerosol for rapid pulmonary absorption with minimal side effects; it also demonstrates potent cardiotonic effects surpassing those of digitalis glycosides and shows antiarrhythmic electrophysiological properties. |
InChIKey |
PBSOJKPTQWWJJD-ZBDZJSKLSA-N |